Non-Small Cell Lung Cancer
The Prescription Drug User Fee Act action date is expected in the third quarter of 2025.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
The bispecific antibody, which recently received FDA accelerated approval, showed a response rate of 29% in NSCLC.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
Advertisement
Section Editor
Stephen V. Liu, MDThoracic Medical Oncologist | Georgetown University
Advertisement
Latest Lung Cancer News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.